Paper Details

  1. Home
  2. Paper Details

Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.

Author: CalifanoCatello, CapalboSilvana, D'ArcoAlfonso Maria, D'ArenaGiovanni, De FilippiRosaria, Di RenzoNicola, FerraraFelicetto, LaurentiLuca, MarcacciGianpaolo, PintoAntonio, StortiSergio, TarnaniMichela, VigliottiMaria Luigia

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Rituximab, an anti-CD20 monoclonal antibody, was used to treat 14 patients with CLL-associated autoimmune hemolytic anemia. Rituximab demonstrated efficacy and good tolerance, with 22% of patients achieving a complete response and 50% a partial response.
Paper Details　
Original Abstract of the Article :
Autoimmune hemolytic anemia (AIHA) is a well-known complication of chronic lymphocytic leukemia (CLL). In recent years the anti-CD20 monoclonal antibody rituximab has been used for the therapy of steroid-refractory AIHA and autoimmune thrombocytopenia, either idiopathic or in association with CLL. W...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/ajh.20665

データ提供：米国国立医学図書館（NLM）

Rituximab: A New Weapon in the Desert of CLL-Associated AIHA

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. A serious complication of CLL can be autoimmune hemolytic anemia (AIHA), a condition in which the body's immune system attacks its own red blood cells. This study investigates the potential of rituximab, a monoclonal antibody used to treat certain cancers, in treating CLL-associated AIHA. The researchers found that rituximab effectively increased hemoglobin levels and improved overall clinical outcomes in patients with CLL-associated AIHA. This research is like discovering a powerful weapon in the desert of CLL-associated AIHA, offering a potential solution for a challenging medical problem.

Rituximab: A Promising Treatment for CLL-Associated AIHA

The study's findings suggest that rituximab could be a valuable treatment option for patients with CLL-associated AIHA. The researchers observed a significant improvement in hemoglobin levels and overall clinical outcomes in those treated with rituximab. This research is like a map leading us towards more effective treatments for CLL-associated AIHA, offering hope for a more positive future for those battling this challenging condition.

Navigating the Desert of CLL-Associated AIHA with Rituximab

This study highlights the potential of rituximab as a treatment for CLL-associated AIHA. The researchers' findings suggest that rituximab could be an effective and well-tolerated alternative treatment, offering hope for those struggling with this complex condition. This research is like a caravan traversing the desert of CLL-associated AIHA, leading us toward a better understanding of this condition and the development of more effective treatments.

Dr.Camel's Conclusion

This study provides valuable insights into the potential of rituximab as a treatment for CLL-associated AIHA. The researchers have demonstrated the effectiveness of rituximab in improving clinical outcomes, offering a beacon of hope for those battling this challenging condition. This research is like a journey through the desert of CLL-associated AIHA, leading us towards a better understanding of this condition and the development of more effective treatment options.

Date :
  1. Date Completed 2007-10-09
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

16823816

DOI: Digital Object Identifier

10.1002/ajh.20665

Related Literature

Article Analysis
・Side Effects of fludarabine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.